KatherineNWeilbaecherMD
Oncology • Saint Louis, MOAssociate Professor, Internal Medicine, Washington University School of Medicine
Dr. Weilbaecher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1995
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1993 - Present
MO State Medical License 2000 - 2025
MA State Medical License 1994 - 2001- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients Start of enrollment: 2006 Jan 01
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
- LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- HTLV-1 infected T cells cause bone loss via small extracellular vesicles.Nitin Kumar Pokhrel, Amanda R Panfil, Haniya Habib, Shamreethaa Seeniraj, Ancy Joseph
Journal of Extracellular Vesicles. 2024-10-01 - BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.Muheng Liao, Jace Webster, Emily M Coonrod, Katherine N Weilbaecher, Christopher A Maher
Clinical Breast Cancer. 2024-06-01 - 3 citationsp38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy.Douglas V Faget, Xianmin Luo, Matthew J Inkman, Qihao Ren, Xinming Su
Cancer Discovery. 2023-06-02
Journal Articles
- Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone LossKatherine Weilbaecher, MD, Clinical Cancer Research
- The β3‐Integrin Endothelial Adhesome Regulates Microtubule‐Dependent Cell MigrationKatherine Weilbaecher, MD, Molecular Systems Biology
Press Mentions
WashU Professor on the Importance of Breast Cancer ScreeningsOctober 23rd, 2024
Capitol Dome to Be Lit Pink to Honor Breast Cancer PatientsOctober 18th, 2018
Grant Support
- Next Generation Approaches To Breast Cancer Using Image Guided Drug DeliveryNational Cancer Institute2011–2012
- Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2003–2012
- Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2009
- Microphthalmia In Osteoclast DevelopmentNational Institute On Aging2000–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
